

REVIEW



New advances in skin cancer treatment: How medical innovations are improving patient outcomes

James Guidoboni¹, Fereshteh Aremu² and Laurence Derosa³

¹Department of Dermatology and CIC, Université de Paris, France

²Department of Medicine, King Saud University, Saudi Arabia

³Departments of Dermatology and Medicine, Uniformed Services University, United States

ABSTRACT

Recent developments in skin cancer treatment have brought significant advancements, particularly in the field of immunotherapy. One of the most promising approaches is the use of checkpoint impediments, similar as pembrolizumab and nivolumab. These specifics work by blocking proteins that help the vulnerable system from attacking cancer cells, allowing the body's natural defenses to fete and destroy nasty growths. They've shown remarkable success in treating advanced carcinoma and other aggressive forms of skin cancer. In addition to immunotherapy, targeted curatives have also surfaced as an effective treatment option. These curatives concentrate on specific inheritable mutations set up in cancer cells, enabling largely precise treatment with smaller side goods compared to traditional chemotherapy. Another innovative approach is photodynamic remedy (PDT), which involves using a light-sensitive medicine that, when actuated by a specific wavelength of light, widely destroys cancerous cells while minimizing damage to healthy apkins. PDT is particularly useful for treating superficial skin cancers and precancerous lesions. Arising technologies similar as Tumor- Insinuating Lymphocyte (TIL) remedy offer new stopgap for cases with advanced carcinoma. This substantiated approach involves rooting vulnerable cells from a case's excrescence, expanding them in a laboratory, and introducing them to enhance the body's capability to fight cancer.

KEYWORDS

Skin cancer treatment; Advanced melanoma treatment; Immunotherapy for skin cancer; Checkpoint inhibitors; Pembrolizumab therapy; Nivolumab for melanoma; Targeted therapy for cancer

ARTICLE HISTORY

Received 15 October 2024;
Revised 07 November 2024;
Accepted 15 November 2024

Introduction

Skin cancer is one of the most common malignancies worldwide, with cases increasing due to factors such as prolonged sun exposure, genetic predisposition, and environmental influences. While traditional treatments like surgery and chemotherapy have been effective in managing various forms of skin cancer, they often come with significant challenges, including recurrence risks, side effects, and damage to healthy tissues [1]. Recent medical advancements have paved the way for more precise and less invasive treatment options, significantly perfecting patient issues.

One of the most groundbreaking developments in skin cancer treatment is immunotherapy, particularly the use of checkpoint impediments like pembrolizumab and nivolumab [2]. These medicines help the vulnerable system fete and attack cancer cells by blocking proteins that suppress vulnerable responses. Immunotherapy has demonstrated remarkable success, especially in treating advanced carcinoma and aggressive skin cancers [3]. Alongside immunotherapy, targeted therapy has emerged as a crucial advancement, focusing on genetic mutations within cancer cells. By targeting specific molecular pathways, these treatments offer more effective and personalized approaches with fewer side effects [4].

Additionally, photodynamic therapy (PDT), which utilizes a light-sensitive drug activated by specific wavelengths, has gained recognition as a non-invasive treatment for superficial

skin cancers [5]. Excrescence Insinuating Lymphocyte (TIL) remedy represents another promising invention, using a case's vulnerable cells to enhance their natural capability to fight cancer. These improvements continue to review skin cancer treatment, offering stopgap for bettered survival and quality of life [6].

Recent Advances in Treatment

Immunotherapy

Immunotherapy is a revolutionary approach that enhances the body's natural capability to fight cancer. Unlike traditional treatments like chemotherapy, which directly target cancer cells, immunotherapy strengthens the vulnerable system so it can fete and destroy nasty cells.

- Checkpoint inhibitors (e.g., pembrolizumab, nivolumab): Cancer cells often evade immune attacks by using specific proteins, such as PD-1 and PD-L1, which act as "checkpoints" that prevent the immune system from attacking them [7]. Checkpoint inhibitors block these proteins, allowing immune cells (T-cells) to recognize and destroy cancer cells effectively.
- Success in advanced melanoma: These drugs have shown great effectiveness, particularly in treating advanced melanoma, by significantly improving survival rates and reducing the risk of recurrence [8].

*Correspondence: Dr. James Guidoboni, Department of Dermatology and CIC, Université de Paris, France, e-mail: guidobonijames@gmail.com

© 2024 The Author(s). Published by Reseapro Journals. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Targeted therapy

Targeted therapy focuses on specific genetic mutations found in cancer cells, making treatment more precise and reducing unnecessary damage to healthy tissues.

- **BRAF and MEK inhibitors:** Many melanomas carry mutations in the BRAF gene, leading to uncontrolled cell growth and tumor progression. BRAF inhibitors, such as Vemurafenib and Dabrafenib, work by blocking the abnormal BRAF proteins, effectively slowing or stopping cancer growth [9]. Additionally, MEK inhibitors, including Trametinib and Cobimetinib, target the MEK protein, which functions alongside BRAF in the same cancer cell growth pathway. These inhibitors are often combined in treatment, leading to better response rates and longer-lasting effects, making them a transformative advancement in melanoma therapy by significantly improving patient outcomes and reducing the risk of disease progression [10].

Photodynamic therapy (PDT)

PDT is a non-invasive treatment that selectively destroys cancer cells with minimal damage to surrounding healthy tissue.

- **How it works:** Photodynamic therapy (PDT) is a specialized treatment that uses a light-sensitive drug, also known as a photosensitizer, which can be either applied to the skin or injected into the bloodstream. After an appropriate period, allowing the drug to concentrate in cancerous cells, a specific wavelength of light is directed at the affected area [11]. This light activates the drug, triggering a reaction that produces a special form of oxygen capable of destroying cancer cells while leaving surrounding healthy tissue unharmed. PDT is widely used for treating superficial skin cancers and precancerous growths, offering a precise, minimally invasive alternative to surgery [12].
- **Effectiveness in superficial skin cancers:** Photodynamic therapy (PDT) is especially beneficial for treating early-stage basal cell carcinoma (BCC), actinic keratosis, and squamous cell carcinoma (SCC). This approach effectively targets cancerous and precancerous cells while preserving healthy tissue. One of the key advantages of PDT is its cosmetic benefit, as it significantly reduces scarring compared to traditional surgical methods [13]. Additionally, the recovery time is shorter, making it a preferred option for patients concerned about both effectiveness and appearance. Due to its minimally invasive nature, PDT is widely used for skin cancers in visible areas such as the face, neck, and hands.

Tumor-infiltrating lymphocyte (TIL) therapy

TIL therapy is an advanced personalized immunotherapy that enhances the body's natural ability to fight cancer.

- **How it works:** Tumor-infiltrating lymphocytes (TILs) are immune cells naturally present within tumors, working to combat cancer. To enhance their effectiveness, these TILs are collected from the patient's tumor, then multiplied in large numbers under controlled laboratory conditions. Once they reach a sufficient quantity, the expanded TILs are reintroduced into the patient's bloodstream, strengthening

the body's natural immune response [14]. This method improves the immune system's ability to identify and destroy cancer cells more efficiently. TIL therapy is considered a promising treatment, particularly for advanced melanoma, offering a more personalized approach to cancer treatment with the potential for better outcomes.

- **Potential in treating advanced melanoma:** Tumor-Infiltrating Lymphocyte (TIL) therapy has shown significant success in treating metastatic melanoma, especially in patients whose cancer has spread and who have not responded well to other treatments. This approach utilizes the patient's own immune cells, making it a highly personalized form of cancer therapy [15]. Since TIL therapy does not rely on foreign substances, it reduces the risk of rejection and lowers the chances of severe side effects. By strengthening the body's natural defense mechanisms, this treatment offers new hope for patients with advanced-stage cancer, improving their ability to fight the disease more effectively [16].

New Surgical Techniques

New surgical techniques have greatly improved skin cancer treatment, particularly with Mohs surgery, which ensures precise tumor removal while preserving as much healthy tissue as possible. This method involves removing cancerous layers of skin one at a time and examining each under a microscope until no cancer cells remain [17]. By doing so, it maximizes the chances of complete cancer removal while minimizing damage to surrounding healthy skin. Mohs surgery is especially beneficial for high-risk areas like the face, where tissue preservation is crucial. These advancements help reduce recurrence rates and improve cosmetic outcomes for patients undergoing skin cancer treatment.

Conclusions

Advancements in skin cancer treatment have revolutionized patient care, offering more precise and effective solutions with fewer side effects. Immunotherapy, particularly checkpoint inhibitors like pembrolizumab and nivolumab, has significantly improved survival rates by enhancing the immune system's ability to target cancer cells. Targeted therapies, including BRAF and MEK inhibitors, provide personalized treatment options for genetic mutations, increasing treatment success. Photodynamic therapy (PDT) offers a non-invasive approach for superficial skin cancers, while Tumor-Infiltrating Lymphocyte (TIL) therapy utilizes a patient's own immune cells to fight advanced melanoma.

Surgical innovations, especially Mohs surgery, have further refined cancer removal techniques, ensuring minimal damage to healthy tissue and reducing recurrence risks. These modern medical breakthroughs have led to higher cure rates, improved cosmetic outcomes, and better quality of life for patients. As research continues, emerging therapies hold the promise of even more effective and personalized skin cancer treatments, bringing hope for better survival and long-term disease management.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

1. Borgheti-Cardoso LN, Viegas JS, Silvestrini AV, Caron AL, Praca FG, Kravicz M, et al. Nanotechnology approaches in the current therapy of skin cancer. *Adv Drug Deliv Rev.* 2020;153:109-136. <https://doi.org/10.1016/j.addr.2020.02.005>
2. Linck RD, Costa RL, Garicochea B. Cancer immunology and melanoma immunotherapy. *An Bras Dermatol.* 2017;92(6):830-835. <https://doi.org/10.1590/abd1806-4841.201756511>
3. Paulson KG, Lahman MC, Chapuis AG, Brownell I. Immunotherapy for skin cancer. *Int Immunol.* 2019;31(7):465-475. <https://doi.org/10.1093/intimm/dxz012>
4. Bergholz JS, Wang Q, Kabraji S, Zhao JJ. Integrating immunotherapy and targeted therapy in cancer treatment: mechanistic insights and clinical implications. *Clin Cancer Res.* 2020; 26(21):5557-5566. <https://doi.org/10.1158/1078-0432.CCR-19-2300>
5. Griffin LL, Lear JT. Photodynamic therapy and non-melanoma skin cancer. *Cancers.* 2016;8(10):98. <https://doi.org/10.3390/cancers8100098>
6. Lin B, Du L, Li H, Zhu X, Cui L, Li X. Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully. *Biomed Pharmacother.* 2020;132:110873. <https://doi.org/10.1016/j.biopha.2020.110873>
7. Alturki NA. Review of the immune checkpoint inhibitors in the context of cancer treatment. *J Clin Med.* 2023 ;12(13):4301. <https://doi.org/10.3390/jcm12134301>
8. Zhu Z, Liu W, Gotlieb V. The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond. *Crit Rev Oncol Hematol.* 2016;99:91-99. <https://doi.org/10.1016/j.critrevonc.2015.12.002>
9. Tian Y, Guo W. A review of the molecular pathways involved in resistance to BRAF inhibitors in patients with advanced-stage melanoma. *Med Sci Monit: Int J Exp Clin Res.* 2020;26:e920957-9209571. <https://doi.org/10.12659/MSM.920957>
10. Roskoski Jr R. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. *Pharmacol Res.* 2017;117:20-31. <https://doi.org/10.1016/j.phrs.2016.12.009>
11. Kwiatkowski S, Knap B, Przysupski D, Saczko J, Kędzierska E, Knap-Czop K, et al. Photodynamic therapy—mechanisms, photosensitizers and combinations. *Biomed Pharmacother.* 2018; 106:1098-10798. <https://doi.org/10.1016/j.biopha.2018.07.049>
12. Tampa M, Sarbu MI, Matei C, Mitran CI, Mitran MI, Caruntu C, et al. Photodynamic therapy: A hot topic in dermato-oncology. *Oncol Lett.* 2019;17(5):4085-4093. <https://doi.org/10.3892/OL.2019.9939>
13. Farberg AS, Marson JW, Soleymani T. Advances in photodynamic therapy for the treatment of actinic keratosis and nonmelanoma skin cancer: a narrative review. *Dermatol Ther.* 2023;13(3):689-716. <https://doi.org/10.1007/s13555-023-00888-1>
14. Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H, et al. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?. *Front Immunol.* 2022;13:1018962. <https://doi.org/10.3389/fimmu.2022.1018962>
15. Rohaan MW, Van Den Berg JH, Kvistborg P, Haanen JB. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. *J Immunotherapy Cancer.* 2018;6(1):102. <https://doi.org/10.1186/s40425-018-0391-1>
16. Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. *J Invest Dermatol.* 2021;141(1):23-31. <https://doi.org/10.1016/j.jid.2020.03.943>
17. Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. *Ann Oncol.* 2019;30(12):1902-1913. <https://doi.org/10.1093/annonc/mdz398>